Christopher W. Lee

Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study

Glenwood Goss, Andrew Arnold, Frances A. Shepherd et al. · Journal of Clinical Oncology · 2009 · 244 citations

Medicine, Oncology, Pharmacology +16

Phase II Study of Vandetanib or Placebo in Small-Cell Lung Cancer Patients After Complete or Partial Response to Induction Chemotherapy With or Without Radiation Therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20

Andrew Arnold, Lesley Seymour, Michael Smylie et al. · Journal of Clinical Oncology · 2007 · 196 citations · Full text

Medicine, Oncology, Pharmacology +17

Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial

Frances A. Shepherd, Michael Millward, Lesley Seymour et al. · The Lancet Oncology · 2014 · 128 citations

Medicine, Oncology, Pharmacology +10

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial

Quincy S. Chu, Laurent Greillier, Wei Tu et al. · The Lancet · 2023 · 101 citations

Medicine, Oncology, Pharmacology +15

Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor–Induced Skin Toxicities in Patients With Metastatic Lung Cancer

Barbara Melosky, Helén Anderson, Ronald L. Burkes et al. · Journal of Clinical Oncology · 2015 · 95 citations

Medicine, Oncology, Pharmacology +16